Finally, we will discuss the current molecular rationale that anti‐PS, anti‐TAM, and anti‐PD‐L1 based therapeutics may have therapeutic value as combinatorial checkpoint inhibitors in cancer immunotherapy. Here, CD274 is linked to cancer.